Oestrogens promote tumorigenesis in a mouse model for colitis-associated cancer 
ABSTRACT Background
Hormone replacement therapy increases the risk of developing ulcerative colitis in postmenopausal women. Chronic intestinal inflammation predisposes to colon cancer development, but effects of female hormones on colitis-associated cancer development have not been examined.
Aim
To investigate the role of female hormones in the dextran sodium sulfate (DSS)-azoxymethane (AOM) mouse model for colitis-associated cancer.
Design
We performed ovariectomies, or sham operations, on mice, and supplemented these animals with indicated hormones. Additionally, we used oestrogen receptor α or β (Erα or Erβ) mutant mice. To study colitis or colitis-associated cancer, we used DSS only, or DSS and AOM, respectively.
Results
Ovariectomy protects female mice against colitis-associated tumour development. Hormone replacement in ovariectomised mice with either oestradiol (E2), medroxyprogesterone acetate or a combination of both suggests that oestrogens are the ovary-derived factor that promotes tumour development in the context of inflammatory damage. E2-treated animals showed increased clinical symptoms and Il-6 production upon DSS-induced colitis and enhanced epithelial proliferation.
Treatment with E2 markedly increased the numbers of polyps in ovariectomised mice and also strongly promoted tumour progression with all E2-treated animals developing at least one invasive adenocarcinoma, whereas, placebo-treated animals developed adenomas only. Using Er mutant mice, we find that the protumorigenic effect of oestrogen depends on both Erα and Erβ.
Conclusions
Our results suggest that oestrogens promote inflammation-associated cancer development by impairing the mucosal response to inflammatory damage.
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SIgNIFICANCE OF THIS STUDY
What is already known about this subject?
• Female hormones increase the risk for developing inflammatory bowel disease.
• Female hormones protect against sporadic colorectal cancer development.
• Oestrogens have known pro-and antitumorigenic effects.
What are the new findings?
• Endogenous female hormones deteriorate colitis-associated cancer development in vivo.
• Of female hormones, oestrogens are responsible for proinflammatory and protumorigenic effects.
• The effect of oestrogens on development of colitis-associated cancer depends on both oestrogen receptors α and β.
How might it impact on clinical practice in the foreseeable future?
• Our data suggest that care should be taken with prescribing hormone replacement therapy in women with inflammatory bowel disease.
INTRODUCTION
Patients with inflammatory bowel disease (IBD) are at an increased risk of developing colorectal cancer (CRC). The risk of developing CRC correlates with the duration, extent and severity of inflammation 1, 2 .
Factors driving inflammation-associated cancers are different from sporadically occurring cancers as they seem to be driven by a distinct sequence of DNA mutations 3 .
One of the important risk factors for the development of sporadic adenomas and CRC is male gender.
Women have a delayed development of adenomas and colon cancers 4, 5 . This gender disparity may depend on a protective effect of female hormones in premenopausal women. The protective effect of female hormones was suggested by the outcome of the Women's Health Initiative. In these large randomised placebo-controlled trials, the combination of oestrogen and medroxyprogesterone acetate (MPA) reduced the number of colon cancers by 37% compared with placebo at 5 years follow-up 6, 7 . Treatment with oestrogens alone did not significantly affect the risk of colon cancer development 8, 9 .
Recently, it was shown in a large cohort study, that the risk of developing IBD is increased in postmenopausal women who were/are past/current users of female hormones (either oestrogens or oestrogens in combination with progestins) 10, 11 . However, the role of female hormones in colitisassociated cancer development has not been examined. We therefore set out to investigate a role for female hormones in an experimental model for colitis-associated cancer development. In line with the data that suggest a predisposing role for oestrogens in the development of ulcerative colitis, we find that oestrogens promote tumour incidence and progression in the context of intestinal inflammation.
MATERIAL AND METHODS

Animal experiments
All experiments were performed according to the guidelines of the Experimental Animal Center of the 
Polyp counting
After overnight fixation of colons, tissue was rinsed with PBS twice and immersed in 70% ethanol overnight. Subsequently, polyps were counted. Polyp size was estimated using a ruler guide.
DSS scoring system
A standardised scoring system was used to assess the severity of colitis both clinically and histopathologically 14 .
Tissue processing and immunohistochemistry
Immunohistochemistry was performed as previously described 15 . In short, tissue was fixed in 10% icecold formalin embedded in paraffin. Sections of 4 µm were deparaffinised in xylene and rehydrated. 
Cytokine bead analysis
Intestines were lysed in nine volumes of Greenberger lysis buffer using a motorised Turrax homogeniser. The lysis was made out of a 2× buffer containing 150 mM NaCl, 15 mM Tris, 1 mM MgCl2, 1 mM CaCl2 and 1% Triton X-100 pH 7.4 prior to use, the 2× buffer was diluted 1 : 1 with 0.9% NaCl, and to 50 ml buffer 1 tablet protease inhibitor (Roche) was added. Tissues were homogenised on ice, and after homogenisation they were put to rest on ice for 30 min. Subsequently, the lysates were centrifuged for 7 min at 4000 rounds per minute (RPM) at 4°C in a microcentrifuge. The supernatant was put into a clean new tube and centrifuged for 10 min at 14 000 RPM at 4°C, and stored at 20°C for further analysis. Cytokine bead analysis (CBA) was performed on a mouse Th1 cytokine kit (R&D) according to the manufacturer's protocol.
Statistical analysis
All data are presented as mean ± SE of the mean. For animal experiments, a Student t test or a 1-way analysis of variance (ANOVA) test was used. For the analysis of the distribution of polyp size, 2-way ANOVA tests were used. All ANOVA tests were followed by Bonferroni's post-test for multiple comparisons. For survival analysis, Gehan-Breslow-Wilcoxon values were noted for comparison, corrected using Bonferroni's post-test for multiple comparisons, where p<0.05/K was regarded as significant. K was defined as the total number of analyses made.
RESULTS
Female hormones promote tumorigenesis in a mouse model for colitis-associated cancer
To analyse the role of female hormones in intestinal tumorigenesis in the context of inflammation, we used the AOM-DSS model 16 . In this model, an injection with the carcinogen AOM is followed by three subsequent cycles of DSS to induce colitis ( Figure 1A ). DSS causes direct damage to the colonic epithelium, eliciting a wound-healing response that markedly enhances AOM-induced tumorigenesis.
We first examined whether female hormones influence colitis-associated cancer development. In female mice, endogenous production of female sex hormones can be largely abrogated by OVX. We therefore subjected female mice that had undergone OVX, or a sham operation in which the ovaries where left in situ, to the AOM-DSS model. During the cycles of DSS-induced colitis, we noticed that animals in which ovaries had been removed were slightly but not significantly protected from DSSinduced weight loss (data not shown). Surprisingly, we found that females who had undergone OVX were markedly protected from tumour development compared with sham operated mice ( Figure 1B, 7.0 vs 12.0 tumours per colon, P < 0.001). Size distribution of the polyps did not differ between mice that had undergone OVX or a sham procedure ( Figure 1C ). These data suggest that female hormones promote tumorigenesis in the context of inflammation.
Colitis-associated tumorigenesis is promoted by oestrogens
We next set out to investigate which ovarian hormone is responsible for the promotion of colitisassociated cancer development. Therefore, we induced tumours in mice that underwent OVX, and in which we replaced endogenous hormones with slow-release pellets implanted subcutaneously.
Animals were treated with pellets containing the oestrogen oestradiol (E2, 10 μg/kg/day), the progestin (MPA, 3.3 mg/kg/day) or with a combination of both. MPA is a synthetic progestagen that signals through the progesterone receptor, and is widely used as a contraceptive agent. Additionally,
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MPA in combination with oestrogen, was shown to be protective in sporadic colon cancer development in humans. 6 ,7 The concentrations used were based on the IC50 required for inhibition of ovulation in rats, and allosterically converted to mice 17 . To control for placement of the pellet, a placebo pellet was implanted in mice that did not undergo hormone replacement. OVX was performed together with the placement of the pellets 1 week prior to enrolment in the AOM-DSS protocol. Animals that received E2, either as monotherapy or in combination with MPA suffered more DSS-induced weight loss than control animals or animals that had received MPA monotherapy ( Figure 2A , P < 0.01 on day 8 for E2 vs placebo, P < 0.001 on day 8 for E2+MPA vs placebo). This resulted in reduced survival of mice that had received E2 (P < 0.01), but not for animals that had received the combination of E2
and MPA ( Figure 2B ). We treated all groups with 1.5% DSS in the drinking water for a period of 5 days in weeks 1, 4 and 7, since this was the highest level of DSS that was tolerated in E2-treated mice.
Due to the low levels of DSS we gave to all animals, control mice showed minimal clinical symptoms (eg, weight loss, diarrhoea and rectal bleeding). Additionally, control animals developed only few tumours. Mice that received E2 showed a dramatic 10-fold increase in polyp development compared with placebo-treated mice ( Figure 2C ,F, 1.5 vs 16 polyps/mouse in placebo and E2-treated mice, respectively, P < 0.001). In agreement with the survival data, animals that had received MPA together with E2 were partially protected from E2-induced tumorigenesis ( Figure 2C , 5.6 polyps/mouse in MPA+E2-treated mice, P < 0.001). E2 promoted tumour incidence and also tumour progression, as we observed a shift towards larger polyp size in E2-treated mice ( Figure 2D , P < 0.01). To examine how E2 affects mucosal homeostasis, we assessed numbers of proliferating and apoptotic cells in the normal appearing mucosa at the moment of sacrifice. We found that E2 significantly increased the number of Ki-67 positive cells, whereas the number of apoptotic (active caspase-3 positive) cells was very low and unchanged by treatment with E2 ( Figure 2E ). The polyps were assessed by an expert GI pathologist (JR) on one longitudinal microscopic section of the colon of every animal. It was found that all animals treated with E2 developed adenocarcinomas with invasive growth (Figure 2G ), whereas no adenocarcinomas were observed in any of the animals that had received placebo (P < 0.01 Fisher's exact test).
To examine if the tumour-promoting effect of oestrogen was specific to female mice, we also enrolled male mice that had undergone a sham operation in the AOM-DSS model. Similar to females, E2 treatment caused enhanced weight loss and decreased survival in DSS-AOM-treated males (see online Supplemental Figure S1A ,B). Additionally, an increase in tumour number was seen in males receiving E2 compared with placebo (see online Supplemental Figure S1C ), albeit to a lesser extent than in females (3.6 ± 2.7 vs 7.6 ± 3.6, P < 0.05). Likewise, a trend towards larger polyps was observed, although not significant (see online Supplemental Figure S1D ). Thus, oestrogens promote both tumour incidence and growth in the context of inflammation.
Oestrogens aggravate clinical symptoms of disease, but not histological severity of colitis E2-treated mice showed increased weight loss during the cycles of DSS in the AOM-DSS model. At the time of sacrifice however, the weight of different treatment groups had reverted to the levels that had been measured before the start of DSS-AOM. Weight loss is a sensitive measure of the severity of colitis in the DSS model, which in turn is linked to tumorigenesis. Thus, increased severity of colitis could explain the tumour-promoting properties seen in animals treated with E2. Although previous reports have shown colitogenic effects of E2, these experiments were performed without OVX, in the presence of endogenous hormone production 18 . We therefore repeated these experiments and examined if E2 may aggravate DSS-induced colitis. As in the previous experiment, we subjected mice to OVX and injected these animals with E2 or placebo pellets. They subsequently received a high dose of DSS (2.5%) in their drinking water for 7 days.
E2 aggravated colitis development as judged by clinical symptoms: weight loss, diarrhoea and rectal blood loss ( Figure 3A ,B, see online Supplemental Figure S2A ). However we observed no significant differences in the histopathological score of colitis that was scored by an expert gastrointestinal pathologist (JR), blinded to the treatment of the mice (see online Supplemental Figure S2B ). As in the AOM-DSS experiment, E2 replacement increased the rate of proliferation in DSS-treated animals, but However, there may be differences in the way in which these receptors modulate tumorigenesis.
Oestrogen signalling promotes tumorigenesis through both Erα and Erβ
E2 signals through two distinct oestrogen receptors (Erα and Erβ
Based on the DSS-induced weight loss, we find that Erα promotes tumorgenesis by aggravating inflammation, whereas, Erβ has inflammation-independent effects on tumours in the context of intestinal inflammation.
DISCUSSION
The large prospective randomised trials of the Women's Health Initiative have firmly established that hormone replacement therapy with a combination of oestrogen and MPA protects against the development of CRC [6] [7] [8] . Recently, large epidemiological studies have suggested that oestrogens promote the development of ulcerative colitis 10, 11 . We find that ovariectomised mice are protected against the development of colitis-associated cancer development. Using different combinations of replacement therapy, we find that oestrogens promote colitis-associated cancer development.
Additionally, oestrogens promote clinical signs of colitis, such as weight loss and the severity of diarrhoea, but had no effects on histological scores as judged by H&E staining. The increased clinical symptoms correlated with elevated Il-6 production, but levels of Tnfα, Il-12 and Il-10 were not affected by oestrogens. A colitogenic effect of oestrogens in the DSS model has previously been reported by others in mice that had not undergone OVX 18 . In these experiments, it was shown that oestrogens aggravate DSS-induced colitis both clinically and histologically. In our experiments, we By contrast, in Erβ mutant littermates, the distribution of polyp size was similar between E2 and placebo-treated mice * = P < 0.05, ** = P < 0.01, *** = P < 0.001. function of Erα, since these animals lack both endogenous and exogenous oestrogens. Our studies contrast with a recent report that suggests that Erβ mutant mice have increased tumour development in the AOM-DSS model of colitis-associated cancer development 20 . In this study, it was found that Erβ mutant mice have a more rapid tumour development compared with wild-type littermates in the AOM-DSS model. The Erβ mutants had an increased number of tumours at week 9, whereas tumour load was equal to wild-type mice at week 16. The most noticeable difference between the two experimental approaches is the fact that we performed OVX in all our studies, thereby abrogating endogenous sex hormone production, whereas in the study by Saleiro et al, the ovaries were left in situ. OVX plus oestrogen replacement is often performed in Er mutant mice as the lack of one of the receptors may modulate oestrogen levels and affect signalling through the remaining receptor. A well known example is the increased plasma levels of oestrogens that are present in Erα mutant mice 21 . A similar effect may exist in Erβ mutant mice, as Erβ plays an important role in the ovaries where it is expressed in the granulosa cells and regulates granulosa cell differentiation 22 . Erβ mutant mice display aberrant regulation of oestrogen production by the ovaries 22 which may influence outcomes in animal models. These effects can be circumvented by performing OVX plus hormone replacement.
In the AOM-DSS model, tumorigenesis depends on DSS-induced tissue damage and the subsequent epithelial repair. It has recently been demonstrated that efficient repair of inflammatory mucosal injury is important to prevent ongoing inflammation and epithelial proliferation 23 . This was demonstrated in Egfr mutant mice which show an impaired epithelial response to a proinflammatory environment on an Il-10 mutant background resulting in an exaggerated response to DSS with overexpression of proinflammatory cytokines, excess weight loss and increased mortality. The mice showed a particular overexpression of Il-6, a cytokine that plays a key role in colitis-associated cancer development 24, 25 . This excess production of Il-6 likely plays a key role in the ongoing proliferative response in both Egfr mutant and E2-treated mice. Finally, the Egfrmutant mice develop more tumours on an Il-10 mutant background and show enhanced tumour progression with development of invasive adenocarcinomas. Thus, E2 may promote colitis-associated colon cancer development by impairing the resolution of inflammatory injury similar toEgfr mutant mice.
Increased production of Il-6 in E2-treated mice may be the result of impaired mucosal repair, but may also be more direct. It was previously shown that oestrogens promote the production of Il-6 in peritoneal macrophages in vitro and in vivo 26 . Similar to our own results in these macrophages, oestrogens had no effect on Il-12 production and only little effect on Tnfα 26 . On the other hand, the effect of oestrogens on Il-6 production in the context of colitis is in contrast with studies showing that oestrogens inhibit Il-6-dependent bone resorption 27 , and can suppress Il-6-dependent tumorigenesis in the liver 28 . This suggests that effects of oestrogens on Il-6 production are highly context-dependent.
In conclusion, we find that oestrogens increase severity of colitis and colitis-associated cancer development. Both Erα and Erβ are required for the tumour-promoting role of oestrogens. The tumour-promoting properties of oestrogens correlate with increased production of Il-6 and an exaggerated proliferative response of the colonic epithelium which may indicate that E2 compromises mucosal repair after inflammatory injury. Since colitis-associated cancer development is a relatively rare occurrence, there is no clinical information on the effect of female hormone replacement in the development of colitis-associated cancer in humans. Our results seem to suggest, however, that care should be taken to assure that women with ulcerative colitis who are on hormone replacement therapy, undergo adequate colonoscopy screening for colon cancer development. 
